Treatment of multiple myeloma has evolved over the last decade, most notably with the introduction of highly effective novel agents. It is now possible to aim for deep disease responses in a greater number of patients in an attempt to prolong remission duration and survival. Initially introduced in the relapsed setting, the novel agents, namely thalidomide, bortezomib and lenalidomide, are now being increasingly incorporated into upfront treatment strategies, raising questions about the feasibility of 'retreatment' with such agents. Also, in a disease that is characterized by multiple relapses, the 'sequencing' of the different effective options is an important question. In the frontline setting, the first remission is likely to be the period during which patients will enjoy the best quality of life. Thus, the goal should be to achieve a first remission that is the longest possible by using the most effective treatment upfront. At relapse, the challenge is to select the optimal treatment for each patient while balancing efficacy and toxicity. The decision will depend on both disease-and patient-related factors. This review aimed to assess the available research data addressing 'retreatment' approaches, drug 'sequencing' and the long-term impact of upfront therapy with novel drugs.
Introduction
The treatment of multiple myeloma (MM) has evolved substantially over the last decade, most notably with the introduction of highly effective novel agents, the use of which has resulted in considerable improvements in outcome, mostly in younger patients. [1] [2] [3] [4] Initially introduced in the relapsed setting, these novel agents, namely thalidomide, bortezomib and lenalidomide, are now being increasingly incorporated into upfront treatment strategies, raising new questions about the feasibility of retreatment with such agents as well as what is the best sequence of treatment for each individual patient. These agents have been extensively studied in the relapsed or refractory setting, and several reviews have already been published. [5] [6] [7] [8] [9] The recapitulation of these studies is beyond the scope of this review which primarily aimed to focus on the available research data addressing retreatment approaches, drug sequencing and the long-term impact of upfront therapy with novel drugs. For the purpose of this review, relapsed and refractory MM were defined according to the International Myeloma Workshop Consensus, 10 as described in Supplementary Document No.1, and we have followed published guidelines for medical literature reviews. 11, 12 General considerations in the MM treatment paradigm at relapse
Goals for treatment at relapse
One of the keypoints related to the use of novel agents is the capacity to induce high-quality responses, particularly complete responses (CRs). 13 For newly diagnosed MM, the correlation between the depth of response and survival is now widely accepted for patients in the transplant setting, 14, 15 both with the use of conventional [16] [17] [18] [19] and novel agents. 20, 21 In the nontransplant setting, this association is not yet fully established, 22 although the important impact of CR on survival has been suggested in recent studies. 23, 24 Recently, Gay et al. 25 reported on the beneficial impact of achieving CR on outcome in 1175 newly diagnosed patients with MM not eligible for autologous stem cell transplantation (ASCT).
In the relapsed setting, the impact of CR on survival is still controversial, and it is unclear whether disease control (that is, duration of response/progression-free survival (PFS)) or the depth of response is more important. Nevertheless, several recent studies have shown a clear relationship between the depth of response and survival in this setting, further demonstrating that a better quality of response may be associated with an improved outcome even beyond frontline therapy. [26] [27] [28] In addition, a recent subanalysis of a phase III trial comparing the combination of pegylated liposomal doxorubicin plus bortezomib vs bortezomib monotherapy in the relapsed setting suggested that the speed of response may also influence outcome. In this analysis, a greater reduction in M-protein after cycle 2 was associated with a longer time to progression (TTP). 29 Finally, it is noteworthy to highlight that studies that have analyzed outcomes according to the quality of a so-called 'good remission' (that is, CR, near CR and VGPR) have shown that survival was virtually identical in patients who achieved near CR, VGPR and PR, but significantly worse when compared with patients in CR. 16, 25, 30 In this respect, the achievement of a negative minimal residual disease status by multiparameter flow cytometry 31, 32 or by molecular studies 33 appears to be the prerequisite for long-term remission and prolonged survival. Thus, for patients with a good performance status who can tolerate aggressive treatments, the ultimate goal at induction as well as at relapse should be to achieve the deepest possible response in order to improve survival. On the other hand, for patients who cannot tolerate aggressive treatment, disease stabilization with palliative therapy should be employed with the aim of preventing further progression. 34 
Factors determining treatment at relapse
At relapse, the challenge is to select the optimal treatment for each patient while balancing efficacy and toxicity. The decision will depend on both disease-and patient-related factors. [5] [6] [7] [8] [9] 35 Disease-related factors are influenced by: (1) the quality and the duration of response to previous therapies and (2) the aggressiveness of the disease, such as the presence of extensive bone disease, plasma cell leukemia, extramedullary MM, increased b 2 -microglobulin, decreased albumin or cytogenetic abnormalities. 28, 36, 37 On the other hand, patient-related factors include pre-existing toxicity, such as peripheral neuropathy (PN) or thromboembolic events from upfront therapy and other patientrelated conditions, such as age, performance status, bone marrow reserve and renal function.
'Retreatment' approaches for relapsed myeloma
Novel agents, such as thalidomide, bortezomib and lenalidomide, have been extensively studied in relapsed or refractory disease. [38] [39] [40] [41] [42] [43] [44] [45] [46] However, few studies, if any, have specifically addressed the 'retreatment' and sequencing issues. National
Comprehensive Cancer Network clinical practice guidelines state that patients with MM who are not refractory to their initial therapy (that is, with a relapse 46 months after completion of the previous therapy) may be retreated with the same regimen. 47 Nevertheless, a number of analyses assessing the efficacy and safety of 'retreatment' approaches have been conducted and will be discussed thereafter.
Retreatment with immunomodulatory drugs
The pivotal phase III MM-009 and MM-010 trials, which examined lenalidomide in combination with dexamethasone vs dexamethasone alone, established this combination as an effective treatment option at relapse. 38, 39, 46 A subanalysis of the two trials was conducted to elucidate the impact of prior thalidomide exposure on clinical outcomes (response rates, duration of response, TTP, PFS and overall survival (OS)). This showed that the combination remained significantly superior over dexamethasone alone regardless of prior therapies, including prior exposure to thalidomide. 48 However, in a subgroup analysis of patients treated with lenalidomide and dexamethasone, the overall response rate (ORR) and CR rate were significantly higher in thalidomide-naive vs thalidomideexposed patients, with longer median TTP and PFS in the former group, although OS was not affected by prior thalidomide exposure (36.1 vs 33.3 months, P ¼ 0.2; Table 1 ). All patients in the thalidomide-exposed subgroup, including those who relapsed on or who were refractory to thalidomide, also benefited significantly from lenalidomide plus dexamethasone treatment. The authors concluded that although there might be some degree of cross-resistance between thalidomide and lenalidomide (as suggested by the shorter TTP in the thalidomideexposed patients), there are still benefits for all patients regardless of prior thalidomide exposure. In another corollary subanalysis of the MM-009 and MM-010 trials, lenalidomide plus dexamethasone treatment was found to result in significantly prolonged TTP, PFS, and OS, as well as a better quality of response when used at first relapse as compared with its use in later salvage therapy lines. 49 Moreover, in a large series of patients treated at the Mayo clinic, who had received thalidomide-or lenalidomide-containing regimens upfront and who were retreated with an immunomodulatory drug (IMiD; thalidomide, lenalidomide or pomalidomide) at relapse, it was shown that 'retreatment' with a different IMiD from that used upfront could induce substantial responses, especially pomalidomide after thalidomide or lenalidomide. The use of pomalidomide was associated with a high ORR (up to 83%), while the lowest response rates were observed in patients who were retreated with thalidomide after having received lenalidomide as initial therapy (Table 1) . 50, 51 Finally, in a phase I/II study, Palumbo et al. 52 evaluated dosing, safety and efficacy of the four drug combination bortezomib, melphalan, prednisone and thalidomide (VMPT) in 30 patients with relapsed or refractory disease after 1 or 2 prior lines of treatment. Approximately 30% of these patients had received prior thalidomide-based treatment. In patients who had never received thalidomide before study entry, the hazard ratio of PFS was 0.29 (95% confidence interval, 0.09-0.9; P ¼ 0.03) in comparison with those who received prior thalidomide (summarized in Table 3 ).
Although one must acknowledge that patient numbers were small, the data summarized above indicate that 'retreatment' with an IMiD, mainly lenalidomide, is feasible and can induce high response rates. However, it is noteworthy that most of the currently available data are related to the efficacy of lenalidomide following thalidomide exposure, and there is currently a lack of evidence regarding the efficacy of lenalidomide or pomalidomide treatment at relapse following exposure to lenalidomide upfront. In the future, long-term outcomes of patients in studies that have incorporated lenalidomide in the frontline setting should help shed light on this issue.
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Retreatment with bortezomib
An analysis of the efficacy of treatments at relapse in the phase III VISTA trial, which established the combination of bortezomib, melphalan and prednisone (VMP) over MP alone in the frontline treatment of elderly patients, demonstrated that patients could be effectively treated with bortezomib or IMiDs following frontline bortezomib therapy. 58 In patients treated with bortezomib-based therapy at relapse, an ORR (XPR) of 47% was reported for patients initially randomized to VMP and 59% for patients who initially received MP. Although the response rate to subsequent bortezomib-based therapies appeared somewhat higher in bortezomib-naïve patients of the MP arm, the survival from start of subsequent therapy was not shorter among patients randomly assigned to VMP vs MP (median 30.2 vs 21.9 months; P ¼ 0.21). In fact, there was no survival difference between the two arms from start of subsequent therapy among patients who received bortezomib, thalidomide or lenalidomide as salvage treatments. The authors concluded that patients relapsing after bortezomib-based therapy are not intrinsically more resistant to subsequent therapies as compared with those relapsing after traditional chemotherapy with MP, and they can be successfully treated with subsequent bortezomib-or IMiD-based therapies (Table 2) .
Retreatment with bortezomib was also examined prospectively in a specific phase II study (the 'RETRIEVE' study, ClinicalTrials.gov, Identifier: NCT00431769). In this trial, patients whose disease had responded to previous bortezomib treatment and who had relapsed after X6 months could be retreated with bortezomib (±dexamethasone). 59 A total of 130 patients who received at least one dose of bortezomib-based retreatment were included. Those patients received bortezomib not only in second line, but also in later lines of treatment (up to 4 lines). Retreatment with bortezomib resulted in an ORR (XPR) of B40% with a median TTP of 8.4 months for patients who reached CR/PR ( Table 2 ).
In another analysis of patients who had taken part in the phase II SUMMIT and CREST and phase III APEX trials, and who were retreated with bortezomib (n ¼ 22), an ORR of 50% was observed. 60 Although many of these patients received bortezomib retreatment in combination with other agents, similar response rates could be observed in patients retreated with single-agent bortezomib. Moreover, 2 of 11 patients who responded to retreatment had not responded to the initial bortezomib treatment. 60 Similarly, in a retrospective review of patients (n ¼ 82) who had been treated with two separate lines of bortezomib-based therapy in community oncology clinics (the majority of whom had received single-agent bortezomib both at initial therapy and retreatment), 21% responded to bortezomib retreatment. 61 Although response rates to retreatment were higher in patients who had responded to initial bortezomib treatment, 13% of patients with less than a PR with the initial therapy had an objective response following retreatment. 61 In addition, in a study by Hrusovsky et al. 62 subgroup analyses of the rates of clinical benefit (CR, near CR, PR or stable disease) were performed according to treatment-free interval (TFI) after initial bortezomib therapy (p6 months vs 46 months) and according to concomitant dexamethasone treatment. In patients with a TFI 46 months a higher rate of clinical benefit (89.7%) could be achieved as compared with patients with a TFI p6 months (61.9%).
Concerning the risk of cumulative toxicity with bortezomib retreatment (notably the risk of PN), an analysis of the VISTA trial has shown that the incidence of bortezomib-induced PN was lower during bortezomib maintenance (cycles 5-9) compared with induction cycles (cycles 1-4). After prolonged follow-up, the rate of improvement or resolution of PN events on the VMP arm was 79%, demonstrating that this toxicity was reversible in the majority of cases. 63 In the above mentioned RETRIEVE study, results suggested that there was no evidence for cumulative toxicity with bortezomib retreatment. Notably, while the overall incidence of PN was 40%, this was of grade 3 in 9% with no cases of grade 4. 59 A possible explanation was suggested by the HOVON group who showed an interaction between myeloma-related factors and patient's genetic background regarding the development of treatment-induced PN, with different molecular pathways being implicated in bortezomib-induced PN. 64 From a safety and toxicity perspective, retreatment with bortezomib is further supported by the results derived from regimens using weekly bortezomib dosing schedules [65] [66] [67] or subcutaneous administration. 68 A number of additional prospective and retrospective studies have been conducted to examine retreatment with bortezomib, 62, [69] [70] [71] (Table 2 ) and all of these studies suggest that re-using bortezomib in later lines is feasible and can result in responses in a considerable proportion of patients.
Retreatment with stem cell transplantation
ASCT might be a feasible option at relapse for patients who did not undergo transplantation upfront. In a pioneering trial, Fermand et al. 72 investigated the use of upfront transplantation vs transplantation at relapse in the setting of conventional induction treatments. The results indicated that OS was similar whether transplantation was performed at diagnosis or at the time of relapse, although early transplantation significantly prolonged PFS, as well as the period of time without symptoms, treatments and treatment-related toxic effects. 73 Moreover, following an upfront ASCT, especially after a long period of disease remission, a second ASCT might be an option if an adequate graft is available and the patient has no contraindications due to age, comorbidities or performance status. [74] [75] [76] [77] [78] [79] [80] [81] [82] Three recent retrospective single-center studies support this option and demonstrated that prolonged duration of remission after the first ASCT was associated with improved PFS and OS after the second ASCT. [83] [84] [85] Such a second ASCT can be considered after a progression-free period of at least 1.5-2 years of remission after the first ASCT procedure. 8, 86 However, a third ASCT for patients relapsing after tandem ASCT did not contribute to long-term disease control. 87 Finally, one should acknowledge the feasibility of allogeneic stem cell transplantation with a reduced-intensity conditioning at the time of relapse. 79, 82, 88, 89 Although allogeneic stem cell transplantation cannot be routinely recommended outside clinical trials given the high risk of non-relapse-related morbidity and mortality, it may be an option in a very few selected patients, particularly those with high-risk disease. 8, 90 'Retreatment' approaches for relapsed-and-refractory myeloma
In patients whose disease has relapsed and is refractory to a particular drug, a change in the class of agent is indicated as the disease is likely to have become resistant to that particular class of drug. Primary refractory MM to all currently available agents represents a challenging issue and will not be addressed thereafter. 
In a recent report, the combination of lenalidomide and dexamethasone administered as salvage treatment to 106 patients with relapsed or refractory MM following a prior thalidomide-based treatment resulted in a response of XPR in 56.2% and 61.5% (P ¼ 0.45) of patients with thalidomideresistant and -sensitive disease, respectively. 91 In addition, VGPR rates of 16% and 11.5% were observed in both groups, respectively. The median PFS was 10 and 12 months (P ¼ 0.12), and the median OS was 17 and 18.5 months (P ¼ 0.50), respectively. In this study, patients had received a median of three prior lines of treatment (range, 1-6) and most of them had undergone ASCT (62%) and received bortezomib-based therapy (71%) before lenalidomide treatment. The authors concluded that lenalidomide may be equally effective in heavily pretreated MM patients whether they were resistant or sensitive to a previous thalidomide therapy.
In contrast, the aforementioned subanalysis of the MM-009 and MM-010 trials showed that the presence of thalidomiderefractory disease was associated with a reduction in CR, ORR, TTP and PFS as compared with the results in patients with thalidomide-sensitive disease. 48 Indeed, treatment with lenalidomide plus dexamethasone resulted in an ORR of 50% in thalidomide-refractory vs 64.8% in thalidomide-sensitive patients, with a median PFS of 7 and 9.3 months, respectively. 48 Furthermore, in two published analyses addressing the impact of prior treatments, the presence of thalidomide-refractory disease was found to be an important determinant of poor outcome. 28, 92 Indeed, a prospective analysis of RD (lenalidomideþ dexamethasone) or VRD (bortezomib þ lenalidomide þ dexamethasone) regimens was conducted in 99 patients with relapsedrefractory MM who had received a median of two prior lines of therapy (78% had received prior thalidomide and 82% prior bortezomib). 28 At inclusion, thalidomide resistance was present in 18% and resistance to bortezomib was found in 21% of patients. Multivariate analysis established that thalidomide resistance was associated with a significant reduction in response to treatment, PFS and OS as compared with the results in patients with thalidomide-sensitive disease or those who were thalidomide-naïve. Although no significant impact of bortezomib resistance on response or outcome parameters was observed, it was noted that the addition of bortezomib to RD could not overcome the significant negative effect of thalidomide resistance regarding OS, likely due to the selection of a resistant clone. 28 Another report by Avet-Loiseau et al. 92 who retrospectively analyzed treatment with lenalidomide plus dexamethasone in 207 heavily pretreated patients (median three prior lines (range, 1-10)) showed that prior thalidomide treatment, which was noted in 81% of patients, did not influence PFS or OS in univariate or multivariate analyses. However, patients who had progressed on thalidomide treatment had a shorter PFS and OS compared with patients who had not progressed on treatment. Interestingly, this was observed only for patients who had received prior bortezomib. In addition, the authors showed in a multivariate analysis that prior bortezomib treatment was associated with a trend towards a reduced PFS and OS following lenalidomide plus dexamethasone salvage treatment. As an explanation, the authors suggested that bortezomib may induce resistance to late salvage therapy, which is, however, not supported by the data reported by Dimopoulos et al. 28 The conflicting results outlined above highlight the complicated scenario that a heavily pretreated population represents, and indicate that other factors (patient-or disease-related), may have a role.
Relapsed-and-refractory disease to all 'established' novels agents
Patients resistant to novel agents represent a particularly challenging group. Kumar et al. 93 conducted an analysis which showed that in patients who relapsed on, or were refractory to one of the IMiDs (thalidomide or lenalidomide) as well as bortezomib, the median event-free survival was 5 months and the median OS was 8 months. These patients therefore require novel strategies, such as treatment with newer anti-myeloma agents and sophisticated combinations. 94 Therefore, a number of studies are currently investigating newer anti-MM agents, such as histone-deacetylase inhibitors (for example, panobinostat, romidepsin, vorinostat), heat shock protein 90 inhibitors (tanespimycin), mammalian target of rapamycin inhibitors (temsirolimus in combination with steroids or with already established novel agents), the signal transduction modulator perifosine, monoclonal antibody therapy (for example, siltuximab (anti-IL-6), elotuzumab (anti-CS1)), as well as new IMiDs (for example, pomalidomide) and second-generation proteasome inhibitors (for example, carfilzomib, marizomib (NPI-0052); for a complete review, see Dimopoulos et al. 94 These studies have shown that disease refractory to currently available agents can be responsive to combination regimens incorporating the newer agents (Table 3) .
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Impact of long-term upfront therapy with novel agents on subsequent relapses
At present novel anti-myeloma agents are being tested in the consolidation and maintenance settings following upfront or salvage treatment. Moreover, a number of ongoing studies are currently addressing the question of whether in the era of novel agents, ASCT per se is still necessary or if it may be postponed to relapse. 55, 100 However, the benefits of a continuous treatment must be always balanced against the possible risks, as the longterm impact of these strategies on outcome after relapse is currently unknown.
Thalidomide
Thalidomide is the agent that has been investigated most widely, both in the transplant and non-transplant settings. Although thalidomide maintenance improved response rates and PFS in different studies, 21, [101] [102] [103] [104] [105] [106] this benefit did not always translate into an improved survival. 21, 103, 105, 106 The discrepancy in efficacy outcomes reported in these studies may be explained by several factors, including differences in thalidomide doses and duration, as some trials incorporated thalidomide for a limited duration while in others the agent was administered until relapse. Indeed, in the latter studies, median OS from relapse was found to be significantly reduced for patients randomized to the thalidomide maintenance arm vs those who did not receive maintenance 21, 102, 105, 106 Therefore, it has been postulated that the reduced post-relapse survival in patients with prolonged exposure to thalidomide could be related to the generation of aggressive drug-resistant clones.
Conflicting results have also been observed when thalidomide was combined with MP in the upfront treatment of elderly patients. Several studies have analyzed the efficacy and safety of thalidomide in this setting, 23, [107] [108] [109] [110] [111] [112] and only three showed a survival benefit for MPT over MP. [107] [108] [109] Here also, this has been partly attributed to the fact that thalidomide was administered for a limited duration in the studies conducted by the Intergroupe Francophone du Myélome, 107, 108 whereas it was Agents sequencing for myeloma B Mohty et al Table 3 Overview of recent studies investigating newer agent combinations-overcoming refractory disease Abbreviations : CI, confidence interval; CR, complete response; DOR, duration of response; MM, multiple myeloma; MR, minimal response; nCR, near complete response; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; PR, partial response; Pts, patients; RD, lenalidomide + dexamethasone; SD, stable disease; TFI, treatment-free interval; TTP, time to progression; VGPR, very good partial response, VMPT, bortezomib, melphalan, prednisone and thalidomide; VRD, bortezomib + lenalidomide + dexamethasone. a Only the number of evaluable patients is mentioned.
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given until relapse in the Italian study, 23, 110 which resulted in a significantly reduced OS post-relapse compared with the control arm. Furthermore, in the latter study, bortezomib or thalidomide-based salvage regimens were found to improve survival after progression significantly in patients who received MP at diagnosis (P ¼ 0.0002), but not in those who had already been exposed to thalidomide following diagnosis in the MPT arm (P ¼ 0.34). The authors suggested that the use of maintenance therapy might have increased the incidence of drug-resistant relapses. However, one should recognize that in the HOVON study, which showed a survival benefit for thalidomide maintenance, 109 thalidomide was also given until relapse, suggesting that other mechanisms beyond the risk of inducing drug-resistance are likely to influence the final outcome when maintenance treatment with a novel drug is undertaken, such as components of the induction regimen, dose intensity of the induction and maintenance treatment, sequencing of the drugs or other patient-related variables.
Conversely, in an attempt to investigate the cumulative impact of bortezomib, thalidomide and dexamethasone (VTD) dosing on outcome in the Total Therapy 3 protocol, van Rhee et al. 113 found that administration of a higher cumulative dose of components of the VTD regimen was associated with significant benefits in terms of long-term outcome, whereas premature discontinuation of any of the agents was found to have a negative impact on OS, event-free survival and time to next treatment. Notably, the post-relapse survival duration was not adversely affected by VTD dosing and, moreover, a higher bortezomib dose was found to be associated with a longer post-relapse survival time. van Rhee et al. 113 concluded that these results support the upfront use of all active agents in a dose-dense and dose-intense manner.
Lenalidomide
Lenalidomide is the second IMiD that is being extensively investigated in the consolidation/maintenance setting and promising results have been reported. A subanalysis of 212 patients from the phase III MM-009 and MM-010 trials investigated the impact of administering lenalidomide plus dexamethasone therapy until progression in patients achieving XPR. This analysis found that although there was no significant benefit regarding OS with continued therapy, there was a trend towards improved survival (50.9 months vs 35.0 months; P ¼ 0.0594) for patients who continued therapy vs those who discontinued therapy because of adverse events, withdrawal of consent, or other reasons. 114 Although this data require confirmation, they suggest the absence of a detrimental effect associated with continued lenalidomide and dexamethasone therapy in the relapsed setting.
In the MM-015 prospective phase III trial, which evaluated the efficacy and safety of continuous lenalidomide treatment (melphalan, prednisone and lenalidomide induction followed by lenalidomide maintenance (MPR-R)), vs fixed-duration regimens of MP or melphalan, prednisone and lenalidomide (MPR) in transplant-ineligible patients, Palumbo et al. 57 showed that MPR-R resulted in higher response rates compared with MP.In addition, MPR-R reduced the risk of disease progression by 58% compared with MP with a higher 2-year PFS rate. However, follow-up remains too short in this study to identify significant OS differences between the three groups. Importantly, patients relapsing during MPR-R had a similar duration of second-line treatment (median 55 weeks) compared with those relapsing while on placebo following MPR or MP (median 68 and 54 weeks, respectively). Thus, the authors concluded that outcomes of patients who relapse following continuous lenalidomide were similar to those who relapse following fixed-duration regimens, suggesting that maintenance lenalidomide is not associated with a more aggressive relapse.
In another prospective study, Palumbo et al. 115 evaluated the effect of bortezomib as induction therapy (PAD regimen) before tandem ASCT (melphalan 100 mg/m 2 ) followed by lenalidomide as consolidation-maintenance until relapse in 102 elderly patients. In the per-protocol analysis, the investigators could show that lenalidomide maintenance could upgrade the XVGPR rate from 58% after PAD induction to 86% after maintenance therapy. After a median follow-up of 21 months, the 2-year PFS rate was 69%, and the 2-year OS rate was 86%. The authors concluded that bortezomib as induction before ASCT, followed by lenalidomide as consolidation-maintenance was an effective and well-tolerated regimen. Yet, no data were provided regarding the outcome of these patients after retreatment at relapse, nor regarding the long-term impact of lenalidomide maintenance. 115 Other ongoing studies using lenalidomide as maintenance therapy have also shown encouraging results both in young and elderly patients. 53, 54 Interestingly, in the CALGB trial, exposure to thalidomide or lenalidomide during induction was not found to influence TTP. 54 However, the use of maintenance therapy with lenalidomide raised the issue of secondary primary malignancies in both the CALGB and the Intergroupe Francophone du Myélome studies. 53, 54 Although it is recognized that secondary myelodysplasia or leukemia can be part of the natural history of MM, this issue requires further study to better assess the balance between the risks and benefits of maintenance therapy.
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Bortezomib
Several studies have also assessed the potential use of bortezomib in the consolidation/maintenance setting. In a randomized prospective study comparing bortezomib, melphalan and prednisone (VMP) vs bortezomib, thalidomide and prednisone (VTP) as induction therapy followed by maintenance treatment with bortezomib and thalidomide vs bortezomib and prednisone in the treatment of elderly patients, Mateos et al. 67 showed that maintenance therapy could significantly improve the CR rate (from 24% after induction to 42% in patients assigned for maintenance therapy), PFS (median PFS of 31 months) and TTP (median TTP of 35 months). The data compare favorably with those seen in the VISTA trial, where the median TTP was 24 months. Nevertheless, this longer PFS did not translate into an increased OS compared with the VISTA trial (3-year OS of 70% in this trial vs 68% in VISTA). Therefore, the authors concluded that the final benefit of a prolonged maintenance vs a TFI after an optimized induction regimen, as used in VISTA, remains unknown. 67 Another phase III study examined the efficacy of the four drug combination of bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide (VMPT-VT) compared with VMP treatment alone in untreated MM patients who were ineligible for ASCT. 65, 66 The VMPT-VT regimen was superior to VMP in terms of CR and PFS, but no OS benefit was apparent. Similarly, the phase III GIMEMA trial comparing VTD with thalidomide-dexamethasone (TD) showed that VTD consolidation treatment was associated with significantly higher CR rates and PFS compared with TD consolidation. 119 However, no differences were so far observed in terms of OS. Several other studies recently closed or ongoing support the feasibility and efficacy of bortezomib incorporated into a consolidation/ Agents sequencing for myeloma B Mohty et al maintenance approach. 33, [120] [121] [122] Overall, bortezomib consolidation is well tolerated without a significant increase in toxicity, such as PN. It was found to improve the depth of response and PFS, but clinical benefit in terms of OS has not yet been reported.
Although several ongoing randomized trials are evaluating novel agents in the maintenance setting with encouraging preliminary results, 53, 54, 57, 100, 121, 122 to date very few data are available regarding the optimal duration and the potential risk of refractory relapse after maintenance therapy. Prospective longterm follow-up data from these studies will help shed light on this issue. Currently, a cautious recommendation might be that a limited duration of post-induction/intensification therapy until maximal response is preferable in order to avoid resistant relapse and minimize cumulative side effects.
Optimal sequence of novel agents
The question of how different options should be sequenced is undoubtedly highly individual and is one of the central issues in the treatment of MM.
The exploratory modeling approach
In an attempt to assess optimal treatment sequencing in MM regarding the use of novel agent combinations in the nontransplant setting, Heeg et al. 123 used an exploratory modeling approach to generate a model that would allow for the comparison of OS for different treatment sequences. The model, based on a systematic review of trials of novel agent combinations in the non-transplant setting, included 57 clinical studies involving 83 treatment arms and 8449 patients. It was developed to estimate OS of a particular treatment sequence based on an analysis of the relationship between the depth of response and time to next treatment per line of treatment. The conclusions of this analysis suggested that starting with one of the novel agents (added to the conventional MP regimen) increased OS compared with starting with MP alone. Survival was found to be shortest in those treatment lines in which MP was the first-line treatment, irrespective of what subsequent treatment lines consisted of. Starting with MPT or MPR was found to result in a longer survival than MP, while the longest survival was observed when first-line treatment consisted of VMP. Although these data are derived from a model and have to be interpreted with caution, they reasonably indicate that the choice of first-line treatment is instrumental in determining overall outcome, strongly suggesting that the most effective treatments should be used upfront.
Practical considerations
The duration of first remission and the timing of relapse are key determinants for the treatment strategy at relapse. If relapse occurs after a long remission and a long treatment-free period (412 months), then it is possible to consider the use of an alternative treatment, as well as the treatment employed upfront (that is, 'retreatment' approach) as the disease is likely to have remained sensitive to this treatment. If relapse occurs within a short time (o6-12 months) or while the patient is still undergoing treatment, this likely indicates an aggressive disease (relapsed-and-refractory) that has acquired resistance, warranting the use of an alternative regimen. 34 In addition, the presence of poor-risk clinical features, such as cytogenetic abnormalities, may indicate high-risk disease requiring an approach different from that employed in a 'slowly' relapsing disease. In this case, a more aggressive approach to treatment may be warranted, incorporating sophisticated novel agent combinations, allogeneic stem cell transplantation or enrolment in trials of investigational agents. 36 For transplant-eligible patients, it is feasible to consider 'retransplantation' at the time of relapse if an adequate stem cell graft is available. Patients who are candidates for a second salvage ASCT at the time of relapse need to have enjoyed a reasonable response duration following the first ASCT (42 years in most cases). In case of relapse occurring within 12-18 months from the first ASCT procedure, alternative treatments should be sought, preferably incorporating novel approaches, as such a relapse is associated with a poor outcome. 124 In subsequent relapses, retreatment incorporating previously used agents is feasible as long as a good and sustained response to these agents had been achieved, which would indicate that the disease has remained sensitive to these particular agents. In the nontransplant setting, following a frontline treatment consisting of VMP that was associated with prolonged remission, it is acceptable to consider retreatment with a bortezomib-containing regimen based on the data reviewed above. Similarly, following a good response with MPT upfront, a salvage IMiDcontaining regimen (particularly lenalidomide) is feasible.
The choice of treatment at relapse will also depend on the presence of a limiting toxicity. In case of renal impairment, bortezomib-based regimens have shown the best safety profile. 133, 134 Nevertheless, several recent publications have demonstrated that a lenalidomide-based salvage therapy is feasible in case of renal impairment, provided that dose modifications are implemented. 9, [133] [134] [135] [136] [137] In the presence of PN following upfront thalidomide treatment, both thalidomide and bortezomib should be avoided, and a lenalidomide-containing regimen should be chosen. For patients at risk of thromboembolic or cardiovascular events, a bortezomib-containing regimen may be a valid option although a lenalidomide-based regimen may also be chosen as consensus recommendations regarding thromboembolic prophylaxis have been published. 9, 138 In case of relapsed-and-refractory disease to the available novels agents (that is, IMiDs and bortezomib) enrolment in clinical trials of experimental agents is highly desirable for patients who qualify for inclusion. If patients do not qualify for inclusion in a trial, treatment will be aimed at alleviating symptoms and maintaining quality of life, while stabilizing the disease as much as possible. For those patients, palliative treatment is warranted, using alkylating agents in combination with corticosteroids (that is, oral cyclophosphamide and prednisone) or cis-platin-containing regimens, such as continuous infusion of dexamethasone, cyclophosphamide, etoposide and cis-platin.
Concluding remarks
The introduction of novel agents that target both the tumor cell and its microenvironment into the treatment of MM has considerably improved outcomes and it is now possible to aim for deep responses in a greater number of patients in an attempt to prolong remission duration and OS. Despite substantial progress, numerous questions surrounding the optimal treatment remain, especially as myeloma remains an incurable malignancy in most cases. In a disease that is characterized by multiple relapses, the sequencing of the different effective options is an important question. The first remission is likely to be the period during which patients will enjoy the best quality of life. Thus, the goal should be to achieve a first remission that is Agents sequencing for myeloma B Mohty et al the longest possible by using the most effective treatment upfront. For almost all patients, whether transplant or nontransplant eligible, this will consist of a novel agent-based regimen and in that respect, the results from the various analyses reviewed in this article are encouraging as they suggest that the novel agents can be re-used in subsequent lines of therapy. Ongoing trials will help to answer some of these questions and better define the optimal sequence of treatments for an individual patient situation while balancing efficacy and toxicity.
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